Schering posts boceprevir trial data, including results for patients not helped by other drugsNovember 2nd, 2009 more images
more images
Schering-Plough reports data on hepatitis C drug
NEW YORK — Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.
Hepatitis B doesn't raise pancreatic cancer riskNovember 1st, 2009 WASHINGTON - Contrary to popular opinion, hepatitis B doesn't appear to increase the risk of developing pancreatic cancer, say researchers. However, the overall analysis has revealed that only age is significant predictor for pancreatic cancer.
Extending hepatitis C treatment for liver transplant patients may be beneficialNovember 1st, 2009 WASHINGTON - A study by doctors at Henry Ford Hospital has shown that extending hepatitis C treatment for liver transplant patients results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse. "We found that patients who achieved a sustained virological response were more likely to have had extended treatment.
Human Genome Sciences reports smaller 3Q loss after completing tests of lupus drug BenlystaOctober 29th, 2009 more images
more imagesHuman Genome Sciences books smaller 3Q lossROCKVILLE, Md. — Human Genome Sciences Inc.
Vertex says most patients on telaprevir for hepatitis C had undetectable virus levels in trialOctober 28th, 2009 more images
more imagesVertex drug helps hepatitis C patientsCAMBRIDGE, Mass. — Vertex Pharmaceuticals Inc.
Vertex says telaprevir created immune response in most patients with hepatitis COctober 28th, 2009 more images
more imagesVertex: drug aided immune response to hepatitis CCAMBRIDGE, Mass. — Vertex Pharmaceuticals Inc.
Vertex says most patients who took hepatitis C drug had undetectable virus levels in trialOctober 28th, 2009 more images
more imagesVertex says telaprevir boosted hepatitis responseCAMBRIDGE, Mass. — Vertex Pharmaceuticals Inc.
Vertex Pharma books larger 3rd-quarter loss as collaboration revenue falls, costs increaseOctober 26th, 2009 more images
more imagesVertex loss grows on increased development costsCAMBRIDGE, Mass. — Vertex Pharmaceuticals Inc.
Coffee may be good for chronic hepatitis C patientsOctober 21st, 2009 WASHINGTON - Patients of chronic hepatitis C, who drink three or more cups of coffee daily, have a 53 percent lower risk of liver disease progression than non-coffee drinkers, says a new study. The study, led by Neal Freedman of National Cancer Institute (NCI), found that patients with hepatitis C related cirrhosis who did not respond to treatment benefited from increased coffee intake.
Needle exchange program in Puerto Rico tests syringe vending machine to aid drug addictsOctober 13th, 2009 PR group tests syringe vending machine for addictsSAN JUAN, Puerto Rico — A needle exchange program in Puerto Rico is testing a vending machine that provides drug users with clean syringes after-hours to fight the spread of HIV and hepatitis C. Dr. Jose Vargas Vidot is the founder of Community Initiative, the U.S.
Hepatitis B vaccine at birth 'reduces liver cancer cases'September 17th, 2009 WASHINGTON - There has been a dramatic drop in liver cancer cases among Taiwanese children following the use of hepatitis B vaccine at birth, according to a new study. In July 1984, a universal vaccination program was initiated among newborn children in Taiwan to prevent the hepatitis B virus infection, which can predispose to the development of hepatocellular carcinoma, a primary malignancy of the liver.
Genetic mutation makes some people to rid hepatitis CSeptember 17th, 2009 LONDON - A collaborative study led by Johns Hopkins researchers has uncovered a genetic mutation that gives a person the ability to get rid of Hepatitis C without any treatment. While some of the people with Hepatitis C suffer throughout the life and develop serious liver disease, including cancer, others are able to defeat the infection and get rid of the virus with no treatment.
NJ now urging tests for nearly 5,000 patients in hepatitis B outbreak linked to one NJ doctorSeptember 9th, 2009 NJ: 29 hepatitis B cases tied to one doctorJERSEY CITY, N.J. — New Jersey health officials are urging 2,000 more patients to get tested for hepatitis B and other blood-borne diseases following an outbreak linked to a single doctor's office.
NJ urging tests for nearly 5,000 patients in hepatitis B outbreak linked to one doctorSeptember 9th, 2009 NJ: 29 hepatitis cases tied to 1 doctor's officeTRENTON, N.J. — Several thousand patients of a New Jersey doctor should get tested for blood-borne diseases because of an outbreak linked to his office that has led to more than two dozen being diagnosed with hepatitis B, state health officials said.
Males experience loss of libido during hepatitis-C therapySeptember 1st, 2009 WASHINGTON - Loss of libido and impaired sex is common among those undergoing antiviral therapy for chronic hepatitis C, according to a new study. This is the first time a study evaluating the combination therapy, peginterferon and ribavirin, has identified sexual dysfunction (inability to fully enjoy sexual intercourse) as a side effect.
